PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,853 | -4.1% | 1,818 | +32.4% | 0.00% | 0.0% |
| Q2 2023 | $19,661 | +100.6% | 1,373 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $9,803 | -37.7% | 1,373 | -2.1% | 0.00% | 0.0% |
| Q4 2022 | $15,730 | +1.3% | 1,402 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $15,534 | +31.3% | 1,402 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $11,833 | -38.0% | 1,402 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $19,081 | -83.7% | 1,402 | -76.4% | 0.00% | -50.0% |
| Q4 2021 | $116,879 | -38.7% | 5,942 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $190,738 | -5.2% | 5,942 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $201,137 | +49.3% | 5,942 | +65.7% | 0.00% | +50.0% |
| Q1 2021 | $134,728 | +13.1% | 3,587 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $119,160 | -9.4% | 3,587 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $131,535 | +11.4% | 3,587 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $118,048 | +27.5% | 3,587 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $92,616 | – | 3,587 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,484,274 | $27,873,554 | 11.71% |
| Frazier Life Sciences Management, L.P. | 8,407,152 | $94,328,245 | 5.86% |
| Abingworth LLP | 1,435,106 | $16,101,889 | 5.25% |
| Opaleye Management Inc. | 417,500 | $4,684,350 | 1.63% |
| 683 Capital Management, LLC | 1,350,000 | $15,147,000 | 1.28% |
| Newtyn Management, LLC | 484,074 | $5,431,310 | 1.12% |
| Penn Mutual Asset Management | 62,802 | $704,638 | 0.79% |
| StepStone Group LP | 422,085 | $4,735,794 | 0.62% |
| MPM BioImpact LLC | 195,942 | $2,198,469 | 0.57% |
| Avidity Partners Management LP | 1,900,000 | $21,318,000 | 0.46% |